Can I read Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen‐independent prostate carcinoma on EtoBox?

Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen‐independent prostate carcinoma by Danai D. Daliani; Vasily Assikis; Shi‐Ming Tu; Christos N. Papandreou; Lance C. Pagliaro; Tammy Holtkamp; Xumei Wang; Peter F. Thall; Christopher J. Logothetis is a Medicine article available to read on EtoBox.

What is Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen‐independent prostate carcinoma about?

## Abstract ## BACKGROUND In this Phase II study, the authors assessed the toxicity and anti‐tumor activity of a combination of oral cyclophosphamide, oral low‐dose dexamethasone, and intravenous vincristine (CVD) in patients with metastatic androgen‐independent prostate carcinoma (AI‐PCa). ## METHODS Patients with histologic proof of adenocarcinoma of the prostate progressing despite adequate hormonal therapy and adequate organ function were treated with oral cyclophosphamide, 250 mg/daily (Days 1–14); intravenous vincristine, 1 mg daily (Days 1, 8, 15); and oral dexamethasone, 0.75 mg twice a day (Days 1–14) in 28‐day cycles. Study endpoints were toxicity, rate of prostate specific antigen (PSA) decline > 50%, and/or measurable disease response. ## RESULTS Fifty‐two (95%) of 55 registered patients were evaluable. The majority (65%) of patients had received prior chemotherapy. The median number of treatment cycles given was two (range, one–seven cycles). Twenty‐nine percent of the patients were found to have a > 50% decline in PSA level compared with baseline levels, and 25% of the patients with bidimensionally measurable soft‐tissue or visceral disease were found to have a partia

Who reads Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen‐independent prostate carcinoma?

Author

Danai D. Daliani; Vasily Assikis; Shi‐Ming Tu; Christos N. Papandreou; Lance C. Pagliaro; Tammy Holtkamp; Xumei Wang; Peter F. Thall; Christopher J. Logothetis

Publisher

John Wiley and Sons; Wiley (John Wiley & Sons); John Wiley & Sons Inc.; Wiley (ISSN 0008-543X)

Published

2003

Language

EN

Field

Medicine (Health Sciences)